SIC
REGN icon

SJS Investment Consulting’s Regeneron Pharmaceuticals REGN Stock Holding History

SJS Investment Consulting’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$29.3K Sell
47
-19
-29% -$12.9K ﹤0.01% 649
2026
Q1 		$51K Sell
66
-123
-65% -$94.2K 0.01% 378
2025
Q4 		$146K Buy
189
+39
+26% +$26.5K 0.02% 164
2025
Q3 		$84.3K Buy
+150
New +$84.8K 0.01% 203
2025
Q2 		– Sell
-2
Closed -$1.27K – 1634
2025
Q1 		$1.27K Sell
2
-1
-33% -$688 ﹤0.01% 915
2024
Q4 		$2.14K Sell
3
-5
-63% -$4.2K ﹤0.01% 675
2024
Q3 		$8.41K Hold
8
– – ﹤0.01% 397
2024
Q2 		$8.41K Hold
8
– – ﹤0.01% 356
2024
Q1 		$7.7K Hold
8
– – ﹤0.01% 386
2023
Q4 		$7.03K Sell
8
-3
-27% -$2.47K ﹤0.01% 336
2023
Q3 		$9.05K Hold
11
– – ﹤0.01% 296
2023
Q2 		$7.91K Sell
11
-2
-15% -$1.54K ﹤0.01% 294
2023
Q1 		$10.7K Buy
13
+1
+8% +$754 ﹤0.01% 282
2022
Q4 		$8.66K Buy
12
+6
+100% +$4.43K ﹤0.01% 297
2022
Q3 		$4K Buy
+6
New +$3.78K ﹤0.01% 362
2022
Q1 		$18K Buy
+26
New +$16.4K 0.01% 314

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

SJS Investment Consulting's REGN Position: Q2 2026 in Review

SJS Investment Consulting reduced its Regeneron Pharmaceuticals (REGN) stake by 29% in Q2 2026, selling an estimated $12.9K and leaving 47 shares worth $29.3K. The position accounts for ﹤0.01% of the portfolio, ranked #649.

SJS Investment Consulting first reported a position in REGN in Q1 2022 and has held it in 16 quarters since. The position peaked at $146K in Q4 2025. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • SJS Investment Consulting held 47 shares of Regeneron Pharmaceuticals worth $29.3K as of Q2 2026.
  • SJS Investment Consulting sold 19 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $12.9K.
  • Regeneron Pharmaceuticals made up ﹤0.01% of SJS Investment Consulting's portfolio in Q2 2026, its #649 holding.
  • SJS Investment Consulting first reported a position in Regeneron Pharmaceuticals in Q1 2022 and has held it in 16 quarters since.
  • SJS Investment Consulting's Regeneron Pharmaceuticals position peaked at $146K in Q4 2025.
  • 1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on SJS Investment Consulting's 13F filing for Q2 2026, filed 22 Jul 2026.